November 1, 2017 05:54 AM EDT

AstraZeneca’s asthma drug tralokinumab goes 0 for 3 in PhIII as 2 more trials flop

John Carroll

Editor & Founder

You can write off just about all of the remaining value assigned to AstraZeneca’s asthma drug tralokinumab — if you hadn’t already done so. Outside of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca’s asthma drug tralokinumab goes 0 for 3 in PhIII as 2 more trials flop

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

We’re about to find out which RFK Jr. will show up at HHS

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Astellas shakes up management despite impressive nine-month earnings

Merck CEO says he’s confident in growth despite Gardasil ‘headwind’

As­traZeneca’s asth­ma drug tralok­inum­ab goes 0 for 3 in PhI­II as 2 more tri­als flop

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

AstraZeneca’s asthma drug tralokinumab goes 0 for 3 in PhIII as 2 more trials flop